S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Teva Presents New Data Which Demonstrate Reduction of Injection-Related Adverse Events with the Less Frequent Dosing of Three-times-a-week COPAXONE® (glatiramer acetate injection) 40 mg Compared to Daily COPAXONE® 20 mg|
|Teva Announces Results of Strategic Review of Core Specialty Therapeutic Areas|
|Teva Canada Announces the Launch of (Pr)Teva-Ezetimibe, a Generic of (Pr)Ezetrol® (2014/9/15)|
|Teva Canada Announces the Launch of (Pr)Teva-Escitalopram, a Generic of (Pr)Cipralex®|
|Teva Reports Second Quarter 2014 Results|
|Teva Completes Acquisition of Labrys: Opens Door to a Strong and Novel Migraine Prevention and Treatment Franchise within its CNS Portfolio|
|Teva’s Reslizumab Delivers Clinically and Statistically Significant Reduction in Asthma Exacerbations in Two Pivotal Phase III Studies|
|Teva Presents New Clinical Safety Data in RRMS Patients Treated with Laquinimod for Two or More Years at Joint ACTRIMS-ECTRIMS Meeting|
|Teva Launches SYNCareTM Home Administration Support Program for Patients on SYNRIBO® (Omacetaxine Mepesuccinate) for Injection|
|Teva to Report Second Quarter 2014 Financial Results on July 31, 2014|
Click above to view more mutual fund data and stats for teva - Teva Pharmaceutical Industries Ltd ADR.